Adriamycin Pfs



Indications and Reactions:

Role Indications Reactions
Primary
Breast Cancer 43.1%
Hodgkin's Disease 10.6%
Non-hodgkin's Lymphoma 10.4%
Multiple Myeloma 4.8%
Lymphoma 4.4%
Burkitt's Lymphoma 3.9%
Adult T-cell Lymphoma/leukaemia 2.8%
Diffuse Large B-cell Lymphoma 2.8%
Precursor T-lymphoblastic Lymphoma/leukaemia 2.5%
Acute Lymphocytic Leukaemia 2.2%
Primary Effusion Lymphoma 2.1%
Prostate Cancer 1.7%
Chronic Myeloid Leukaemia 1.5%
Leukaemia Plasmacytic 1.2%
Bone Sarcoma 1.1%
Endometrial Cancer 1.1%
Ill-defined Disorder 1.1%
Hodgkin's Disease Stage Iv 1.0%
Neuroblastoma 1.0%
Breast Cancer Metastatic 0.8%
Febrile Neutropenia 12.5%
Vomiting 8.3%
Sepsis 7.6%
Pneumonia 6.9%
Neutropenia 5.6%
Nausea 4.9%
Pulmonary Toxicity 4.9%
Pyrexia 4.9%
Cardiac Failure Congestive 4.2%
Cardiomyopathy 4.2%
Cellulitis 4.2%
Osteonecrosis 4.2%
Renal Failure Acute 4.2%
Thrombocytopenia 4.2%
White Blood Cell Count Decreased 4.2%
Pancytopenia 3.5%
Pneumonitis 3.5%
Cardiac Failure 2.8%
Colitis 2.8%
Death 2.8%
Secondary
Multiple Myeloma 21.9%
Breast Cancer 16.6%
Hodgkin's Disease 14.7%
Non-hodgkin's Lymphoma 7.0%
Drug Use For Unknown Indication 6.9%
Acute Lymphocytic Leukaemia 4.3%
Diffuse Large B-cell Lymphoma 4.2%
Lymphoma 3.0%
B-cell Lymphoma 2.9%
Product Used For Unknown Indication 2.6%
Chemotherapy 2.5%
Prophylaxis 2.3%
Burkitt's Lymphoma 1.8%
Mantle Cell Lymphoma 1.7%
Breast Cancer Metastatic 1.5%
Bone Sarcoma 1.4%
Adult T-cell Lymphoma/leukaemia 1.3%
Chronic Lymphocytic Leukaemia 1.1%
Hypertension 1.1%
Pain 1.1%
Febrile Neutropenia 10.2%
Pyrexia 8.8%
Vomiting 8.8%
Sepsis 7.5%
Thrombocytopenia 7.1%
Myocarditis 5.2%
Pneumonia 5.2%
Acute Myeloid Leukaemia 4.8%
White Blood Cell Count Decreased 4.6%
Death 4.4%
Neutropenia 4.0%
Hypothyroidism 3.8%
Maternal Exposure During Pregnancy 3.5%
Stomatitis 3.5%
Treatment Related Secondary Malignancy 3.5%
Pancytopenia 3.3%
Hepatitis B 3.1%
Myelodysplastic Syndrome 2.9%
Osteonecrosis 2.9%
Pneumonitis 2.9%
Concomitant
Breast Cancer 18.5%
Multiple Myeloma 16.5%
Chemotherapy 9.6%
Breast Cancer Metastatic 6.8%
Metastases To Bone 6.7%
Pain 5.1%
Prophylaxis 5.0%
Drug Use For Unknown Indication 3.4%
Non-hodgkin's Lymphoma 3.2%
Product Used For Unknown Indication 3.1%
B-cell Lymphoma 3.1%
Hypertension 2.8%
Hodgkin's Disease 2.7%
Depression 2.3%
Diffuse Large B-cell Lymphoma 2.2%
Nuclear Magnetic Resonance Imaging 2.1%
Neoplasm Malignant 2.0%
Lymphoma 1.8%
Eczema 1.5%
Acute Lymphocytic Leukaemia 1.4%
Weight Decreased 12.8%
Vomiting 9.3%
Tooth Extraction 7.9%
Weight Increased 6.5%
Febrile Neutropenia 6.3%
White Blood Cell Count Increased 5.6%
White Blood Cell Count Decreased 4.6%
Wound Drainage 4.6%
Pyrexia 4.4%
Thrombocytopenia 4.0%
Wheelchair User 3.9%
Wound Dehiscence 3.9%
Dyspnoea 3.7%
Wound Treatment 3.7%
Neutropenia 3.5%
Wheezing 3.5%
Wound Secretion 3.3%
Wound Debridement 3.0%
Palmar-plantar Erythrodysaesthesia Syndrome 2.8%
X-ray Abnormal 2.8%
Interacting
Hodgkin's Disease 40.0%
Prophylaxis Of Nausea And Vomiting 20.0%
Anxiety 10.0%
Breast Cancer 10.0%
Bronchopulmonary Aspergillosis 10.0%
Supraventricular Tachycardia 10.0%
Drug Interaction 25.0%
Infusion Site Phlebitis 25.0%
Middle Insomnia 25.0%
Palpitations 25.0%